Paul Rubinstein (@PaulRubinstein4) profile picture

Malignant heme #lymphoma doc #taking care of persons living with HIV and Cancer

Chicago, IL
Joined December 2019
Paul Rubinstein retweeted
SPANISH BROADCAST CALL OF ARGENTINA'S WINNING GOAL IS ELECTRIC 🔥 (Via @TelemundoSports)
286
4,004
330
46,833
1,788,925
Paul Rubinstein retweeted
Breaking news from #CROI2025: Two probable HIV cures, the Chicago and Oslo Patients, were announced. If confirmed, the total number of known cures will rise to 10. Read article: amfar.org/news/researchers-a…
1
5
3
17
9,235
At #CROI2025, our physician researcher @PaulRubinstein4 of @thisisuic @UIHealth presented findings from Chicago Patient (8th person living w/ HIV in remission off #ART after CCR5d32/d32 allogeneic stem cell transplant). @NIAIDNews,#NIAIDVRC,@theNCI & @CookCtyHealth collab vital.
5
3
1,168
Poster presentation at @asco #GU25 by our fellow Dr. Michael Weinfeld looking at low-dose abiraterone adherence/cost vs standard dose abiraterone 💊
4
13
1,246
Congrats to our all ⭐️ graduating fellows!! Dr. Kevin Prescott Dr. Ana Maria Avila Dr. Lucas Maahs We are so excited for what the future holds for you all! @UICancerCenter – at Chicago, IL
1
7
1
39
2,978
Paul Rubinstein retweeted
CONGRESS | #ASH23 | Franck Morschhauser, University of Lille, presents a post-hoc analysis of the POLARIX study on the prevalence & clinical outcomes of molecularly defined subtypes of DLBCL. N=594, high-risk DHL/THL patients with DZsigPos DLBCL may benefit from Pola-R-CHP vs R-CHOP. According to LymphGen classification, EZB, MCD, and unidentified subtypes may benefit from Pola-R-CHP. #lymphoma #lymsm #leusm
1
11
1
29
5,632
Some of our 3rd year fellows Dr. Maahs & Dr. Avila presenting their research @ASH_hematology #ASH23 🩸 @UICancerCenter – at San Diego, CA
4
19
1,382
#ASH23 Thank you to my amazing mentors @Matt_Cortese @Francis77605164 @PaulRubinstein4 and colleagues for visiting my poster and show support! @RoswellHemOnc #lymsm
4
19
833
Paul Rubinstein retweeted
Rutherford et al - BV-AVD v N-AVD in older Hodgkin - SWOG 1836 study, 60y+, n=103 (approx 50 each arm) - med age 66, more high risk in N-AVD - Less tox with N-AVD: GI, PN, sepsis - 1y PFS 64v93% - 1y OS 83v95% (not stat signif) - NRM 4v14% A game changer. #ASH23 #lymsm
26
2
89
11,339
N-AVD vs BV-AVD in older patients with #Hodgkin #lymphoma. No words needed. To me, the new SoC #lymsm #ASH23
4
40
3
134
14,353
Paul Rubinstein retweeted
A prospective approach linking individual level pt reported SDOH data to early adverse AML outcomes. Proud of @EshanaShahMD for an excellent oral abstract and the dedicated efforts of leukemia teams, trainees and patients @UICancerCenter and @LurieCancer
2
8
1
28
4,163
New! Assessment of the safety of nivolumab in people living with HIV with advanced cancer on antiretroviral therapy: the AIDS Malignancy Consortium 095 Study acsjournals.onlinelibrary.wi… @oncoalert @jasonlukemd @AMC_Studies
1
4
1
12
2,656
It is the only way
81
1,959
337
11,582
2,010,242
the best plate ever, though this hiv lymphoma doc is biased
1
2
583
Out today in collaboration with @asco, Dr. Reizine & I discuss why exercise is important for patients with prostate cancer, common challenges & types of exercises that may be helpful! 🏃‍♂️🚴🏽 🧘‍♂️ 🏋🏽‍♀️ #prostatecancer #guonc cancer.net/blog/2023-08/what…
1
9
51
4,864
Paul Rubinstein retweeted
Excited to see the important results of BV-AVD in HIV+ Hodgkin lymphoma in print! 2-yr PFS 87% and OS 92% plus increases CD4/CD8 counts. Great work by Paul Rubinstein and @AMC_Studies sciencedirect.com/science/ar…
4
24
2,137